<DOC>
	<DOCNO>NCT01458275</DOCNO>
	<brief_summary>This 2-week , multicenter , randomize , double-blind , placebo-controlled , parallel group , efficacy safety study ciclesonide nasal aerosol administer daily male premenarchal female subject 6 11 years-old diagnose SAR .</brief_summary>
	<brief_title>A Safety Efficacy Study Ciclesonide Nasal Aerosol Subjects 6-11 Years With Seasonal Allergic Rhinitis ( SAR )</brief_title>
	<detailed_description>This 2-week , multicenter , randomize , double-blind , placebo-controlled , parallel group , efficacy safety study ciclesonide nasal aerosol administer daily male premenarchal female subject 6 11 years-old diagnose SAR . This study consist follow : Screening , Single-blind Placebo Run-in period , Double-blind Treatment period ( period , subject randomize double-blind treatment either ciclesonide nasal aerosol 37 mcg 74 mcg placebo 2 week treatment ) Follow-up . The total duration subject participation approximately 2 month .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Gives write informed consent ( parent/legal guardian ) assent ( child ) , include privacy authorization well adherence concomitant medication withhold period , prior participation . Is male premenarchal female 6 11 yearsold screening . Is general good health ( define absence clinically relevant abnormality determine investigator ) base screen physical examination medical history . Has history SAR relevant dominant seasonal allergen minimum one two year immediately precede study Screening Visit . The SAR must sufficient severity require treatment ( either continuous intermittent ) past expect require treatment throughout entire study period . Has demonstrate sensitivity relevant dominant seasonal allergen know induce SAR base document result standard skin prick test either within 12 month prior screen perform screening visit . A positive test define wheal diameter least 3 mm large control wheal ( normal saline ) skin prick test . The subject 's positive allergen test must consistent medical history SAR , allergen must present subject 's environment throughout study . Subject parent/guardian must possess educational level degree understand English enables communicate suitably Investigator study coordinator well accurately complete Allergic Rhinitis diary Pediatric Rhinoconjunctivitis Quality Life Questionnaire ( PRQLQ ) . Has history physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation ; recent unhealed nasal biopsy ; nasal trauma ; nasal ulcer perforation . Surgery atrophic rhinitis rhinitis medicamentosa permit within 120 day prior screen visit . Has evidence infection , significant anatomic abnormality , ulceration mucosa , blood nose , clinically relevant find nasal examination screen visit . Has nasal jewelry Has participate investigational drug trial within 30 day precede screen visit planning participation another investigational drug trial time trial . Has know hypersensitivity corticosteroid excipients formulation ciclesonide . Has history respiratory infection disorder , include limited bronchitis , pneumonia , influenza , severe acute respiratory syndrome ( SARS ) , within 14 day precede screen visit . Has active asthma require treatment inhale systemic corticosteroid and/or routine use betaagonists controller drug ( eg , theophylline , leukotriene antagonist ) ; intermittent use ( â‰¤ 3 us per week ) inhale shortacting betaagonists acceptable . Use shortacting beta agonist exercise induce bronchospasm allow . Plans travel outside study area ( know pollen area investigative site ) 2 consecutive day Randomization Visit final Treatment Visit . Plans leave study area ( know pollen area investigative site ) long 24 hour Singleblind Placebo Runin period . Is expect use disallow concomitant medication treatment period . Is plan initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior screen visit use stable ( maintenance ) dose ( 30 day ) may consider inclusion . Has nonvaccinated exposure active infection chickenpox measles within 21 day precede screen visit . Initiates pimecrolimus cream 1 % great tacrolimus ointment 0.03 % great study period plan dose escalation study period . However , initiation creams/ointments 30 day prior screen use stable ( maintenance ) dose study period may consider inclusion . Is child relative clinical investigator site personnel , even directly involve study . Has follow condition judge investigator clinically significant and/or affect subject 's ability participate clinical trial : impaired hepatic function ; history ocular disturbance , eg , glaucoma posterior subcapsular cataract herpes simplex ; systemic infection hematological ( include anemia ) , hepatic , renal , endocrine disease ; gastrointestinal disease ; malignancy ( exclude basal cell carcinoma ) ; current neuropsychological condition without drug therapy . Any behavioral condition could affect subject 's ability accurately report symptom caregiver developmental delay , attention deficit disorder , autism . Has condition , judgment investigator , would preclude subject complete protocol capture assessment write . Has receive ciclesonide nasal aerosol previous clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Ciclesonide Nasal Aerosol</keyword>
</DOC>